alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Home › Research › Topic

Amyloid, tau and blood-test diagnosis

5,209 studies in this group. A computer grouped them by what their titles and summaries are about, not by a hand-made list. The name describes most of the group, not every study in it.

Each study has a usefulness score out of 100 (rubric version 4.0). Tap a score to see what makes it up.

Download bibliography of all 5,209 studies, highest score first: BibTeX (.bib) · RIS (.ris)

Highest usefulness score first. Studies without a score come last.

  1. Reelin protects against amyloid β toxicity in vivo

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. Science signaling 2015-07-07 Disease mechanisms

    Alzheimer's disease (AD) is a currently incurable neurodegenerative disorder and is the most common form of dementia in people over the age of 65 years.

  2. Cognitive and Brain Profiles Associated with Current Neuroimaging Biomarkers of Preclinical Alzheimer's Disease

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. The Journal of neuroscience : the official journal of the Society for Neuroscience 2015-07-01 Hippocampus size on brain scans

    The FDG-positive subgroup showed only hypometabolism, predominantly in AD-sensitive areas extending to the whole neocortex, compared with the FDG-negative subgroup.

  3. Different cerebrospinal fluid levels of Alzheimer-type biomarker Aβ42 between general paresis and asymptomatic neurosyphilis

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. European journal of neurology 2015-02-23 Tau biomarkers

    Neurosyphilis is a neurological disease that involves infection of the central nervous system with Treponema pallidum.

    Why it matters

    This study compared Alzheimer-type biomarkers in the spinal fluid of people with general paresis, asymptomatic neurosyphilis, Alzheimer's disease, and normal controls. It found different levels of amyloid-42 between these groups, but it is about diagnosis, not treatment or prevention.

  4. Synaptic therapy in Alzheimer's disease: a CREB-centric approach

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics 2015-01-01 Disease mechanisms

    Therapeutic attempts to cure Alzheimer's disease (AD) have failed, and new strategies are desperately needed.

  5. Olive Oil Phenols as Promising Multi-targeting Agents Against Alzheimer's Disease

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. Advances in experimental medicine and biology 2015-01-01 Prevention trials

    Amyloid diseases are characterized by the deposition of typically aggregated proteins/peptides in tissues, associated with degeneration and progressive functional impairment.

  6. Neuroinflammation in Alzheimer's disease; A source of heterogeneity and target for personalized therapy

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. Neuroscience 2014-10-05 Inflammation and the immune system

    Neuroinflammation has long been known as an accompanying pathology of Alzheimer's disease.

  7. In vivo evaluation of a novel tau imaging tracer for Alzheimer's disease

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. European journal of nuclear medicine and molecular imaging 2014-02-11 Hippocampus size on brain scans

    (18)F-THK523 does not bind to Aβ in vivo, while following the known distribution of paired helical filaments (PHF)-tau in the brain.

  8. Is synaptic loss a unique hallmark of Alzheimer's disease?

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. Biochemical pharmacology 2014-01-09 Disease mechanisms

    Synapses may represent a key nidus for dementia including Alzheimer's disease (AD) pathogenesis.

  9. Brain insulin resistance in Alzheimer's disease and its potential treatment with GLP-1 analogs

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. Neurodegenerative disease management 2014-01-01 Prevention trials

    The prevalence of Alzheimer's disease is increasing rapidly in the absence of truly effective therapies.

  10. Non-pharmacological interventions and neuroplasticity in early stage Alzheimer's disease

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. Expert review of neurotherapeutics 2013-10-17 Prevention trials

    Non-pharmacological interventions have the potential to reduce cognitive decline and to improve psychosocial aspects in mild cognitive impairment and Alzheimer's dementia, and the absence of side effects makes them a favorable option also for preventive strategies.

  11. Modeling Alzheimer's Disease Progression Using Disease Onset Time and Disease Trajectory Concepts Applied to CDR-SOB Scores From ADNI

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. CPT: pharmacometrics & systems pharmacology 2013-10-02 Long-term cohort studies

    Disease-onset time (DOT) and disease trajectory concepts were applied to derive an Alzheimer's disease (AD) progression population model using the clinical dementia rating scale-sum of boxes (CDR-SOB) from the AD neuroimaging initiative (ADNI) database.

    Why it matters

    This study applied disease-onset time and disease trajectory concepts to CDR-SOB scores to model Alzheimer's disease progression. The model could distinguish fast and slow-progressing subgroups and predicted many conversions from mild cognitive impairment to Alzheimer's disease.

  12. Amyotrophic Lateral Sclerosis: An update for 2013 Clinical Features, Pathophysiology, Management and Therapeutic Trials

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. Aging and disease 2013-10-01 End-of-life care

    Amyotrophic lateral sclerosis (ALS), first described by Jean-Martin Charcot in the 1870s, is an age-related disorder that leads to degeneration of motor neurons.

  13. Imaging of tau pathology in a tauopathy mouse model and in Alzheimer patients compared to normal controls

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. Neuron 2013-09-01 Disease mechanisms

    Accumulation of intracellular tau fibrils has been the focus of research on the mechanisms of neurodegeneration in Alzheimer's disease (AD) and related tauopathies.

  14. Alzheimer's disease

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. Seminars in neurology 2013-09-01 Disease mechanisms

    Alzheimer's disease (AD) is the most common neurodegenerative cause of dementia and is responsible for significant individual morbidity and mortality, and economic impact on the health care system.

  15. Dysfunctional synapse in Alzheimer's disease - A focus on NMDA receptors

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. Neuropharmacology 2013-08-22 Disease mechanisms

    Alzheimer's disease (AD) is the most prevalent form of dementia in the elderly.

  16. Amyloid imaging: the court of public opinion

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. Neurology 2013-08-21 Biomarkers

    Human amyloid imaging is one of the great recent translational medicine stories.

    Why it matters

    Amyloid PET imaging lets doctors see beta-amyloid in the living brain, but the authors note it is a surrogate for amyloid pathology and not necessarily a surrogate for an Alzheimer's diagnosis. This paper is a commentary on the history and public perception of amyloid imaging, not a study of a treatment or cure.

  17. The intersection of amyloid β and tau in glutamatergic synaptic dysfunction and collapse in Alzheimer's disease

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. Ageing research reviews 2013-03-22 Disease mechanisms

    The synaptic connections that form between neurons during development remain plastic and able to adapt throughout the lifespan, enabling learning and memory.

  18. Pathologic accumulation of α-synuclein and Aβ in Parkinson disease patients with dementia

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. Archives of neurology 2012-10-01 Disease mechanisms

    Dementia associated with PD has 2 major pathologic subgroups: neocortical synucleinopathy and neocortical synucleinopathy with Aβ deposition.

  19. Is the amyloid hypothesis of Alzheimer's disease therapeutically relevant?

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. The Biochemical journal 2012-09-01 Disease mechanisms

    The conventional view of AD (Alzheimer's disease) is that much of the pathology is driven by an increased load of β-amyloid in the brain of AD patients (the 'Amyloid Hypothesis').

  20. Correlations of CSF tau and amyloid levels with Alzheimer pathology in neuropathologically verified dementia with Lewy bodies

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. International journal of geriatric psychiatry 2012-08-22 Tau biomarkers

    The presence of concomitant Alzheimer pathology has been linked to earlier death in cases with dementia with Lewy bodies (DLB).

    Why it matters

    This study examined whether CSF tau and amyloid levels match brain autopsy findings in people with dementia with Lewy bodies, focusing on co-existing Alzheimer's pathology. It is about improving diagnosis and understanding mixed dementia, not about treatment or prevention.

  21. From mitochondrial dysfunction to amyloid beta formation: novel insights into the pathogenesis of Alzheimer's disease

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. Molecular neurobiology 2012-07-26 Disease mechanisms

    The non-Mendelian sporadic Alzheimer's disease (AD) is the most frequent form of dementia diagnosed worldwide.

  22. An epidemiological study of Alzheimer's disease in elderly Mongolian and Han populations living in rural areas of Inner Mongolia

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. Aging clinical and experimental research 2012-04-25 Risk factors

    This study investigated the current status and distribution of Alzheimer's disease (AD) among Mongolian and Han individuals who were at least 55 years old and living in rural areas of Inner Mongolia.

    Why it matters

    This survey of 9,266 people aged 55 and older in rural Inner Mongolia found an Alzheimer's prevalence of 4.79%, with no significant difference between Mongolian and Han populations, and identified age and gender as risk factors. It provides background data on who is affected but does not test any treatment, cure, or prevention.

  23. Dementia in Parkinson's Disease Correlates with α-Synuclein Pathology but Not with Cortical Astrogliosis

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. Parkinson's disease 2012-04-22 Biomarkers

    Dementia is a common feature in Parkinson's disease (PD) and is considered to be the result of limbic and cortical Lewy bodies and/or Alzheimer changes.

    Why it matters

    This study found that cortical astrogliosis was not associated with cognitive decline in Lewy body-related dementia, though cortical Lewy bodies did correlate with dementia in Parkinson's disease. It is about understanding what drives dementia in these conditions, not about treating, curing, or preventing Alzheimer's.

  24. Use of medical foods and nutritional approaches in the treatment of Alzheimer's disease

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. Clinical practice (London, England) 2012-03-01 Prevention trials

    Alzheimer's disease, the most common cause of dementia, has a high global economic impact.

  25. Nonhuman primate models of Alzheimer-like cerebral proteopathy

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. Current pharmaceutical design 2012-01-01 Disease mechanisms

    Nonhuman primates are useful for the study of age-associated changes in the brain and behavior in a model that is biologically proximal to humans.

From across this topic

10 of the 5,172 studies in this topic, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 10. The same 10 appear here every time.

Other topics